Bitcoin price today: falls to 2-week low below $113k ahead of Fed Jackson Hole
Matinas BioPharma (NYSE:MTNB) Holdings, Inc. (NYSE American:MTNB) announced Monday that it entered into warrant exchange agreements with certain holders of its warrants, according to a statement based on a recent SEC filing. The company’s stock, currently trading at $2.36, has shown remarkable momentum with a 47.5% gain in the past week.
On August 15, the company issued 466,666 shares of its common stock in exchange for the cancellation of an equal number of warrants, each previously exercisable at $17.50 per share. The warrants, originally issued on April 5, 2024, were exchanged on a one-for-one basis for shares of common stock. Following the transaction, the exchanged warrants were cancelled and no additional shares will be issued under those warrants.
The shares were issued without registration under the Securities Act of 1933, relying on the exemption provided by Section 3(a)(9) of the Act.
Matinas BioPharma Holdings, Inc. is incorporated in Delaware and is based in Bedminster, New Jersey. The company’s common stock is listed on the NYSE American under the ticker symbol MTNB.
This information is based on a press release statement included in the company’s Form 8-K filed with the Securities and Exchange Commission.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.